Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer

Abstract

Bladder cancer (BCa) is the sixth most prevalent cancer in men and seventeenth most prevalent cancer in women worldwide. Current treatment paradigms have limited therapeutic impact, suggesting an urgent need for the investigation of novel therapies. To best emulate the progression of human BCa, a pre-clinical intravesical murine model is required in conjunction with existing non-invasive imaging modalities to detect and evaluate cancer progression. Non-invasive imaging modalities reduce the number of required experimental models while allowing for longitudinal studies of novel therapies to investigate long-term efficacy. In this review, we discuss the individual and multi-modal use of non-invasive imaging modalities; bioluminescence imaging (BLI), micro-ultrasound imaging (MUI), magnetic resonance imaging (MRI), and positron emission tomography (PET) in BCa evaluation. We also provide an update on the potential and the future directions of imaging modalities in relation to intravesical murine models of BCa.

Description

Research Article

Keywords

bladder cancer (BCa), murine model, intravesical, bioluminescence imaging (BLI)

Citation

Citation: Relouw, S.; Dugbartey, G.J.; Sener, A. Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer. Cancers 2023, 15, 2381. https://doi.org/ 10.3390/cancers15082381

Endorsement

Review

Supplemented By

Referenced By